Kedrova A - Search Results

1

Cancer Angiogenesis and Opportunity of Influence on Tumor by Changing Vascularization.

Maiborodin I, Mansurova A, Chernyavskiy A, Romanov A, Voitcitctkii V, Kedrova A, Tarkhov A, Chernyshova A, Krasil'nikov S. Maiborodin I, et al. Among authors: kedrova a. J Pers Med. 2022 Feb 22;12(3):327. doi: 10.3390/jpm12030327. J Pers Med. 2022. PMID: 35330327 Free PMC article. Review.

2

[Clinical and anamnestic analysis of multiple primary neoplasms with lesions of the endometrium in women of the Novosibirsk region].

Gerasimov AV, Guliaeva LF, Krasil'nikov SÉ, Kedrova AG. Gerasimov AV, et al. Among authors: kedrova ag. Vopr Onkol. 2014;60(3):335-8. Vopr Onkol. 2014. PMID: 25033686 Russian.

3

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.

Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Wu YL, et al. N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19. N Engl J Med. 2020. PMID: 32955177 Clinical Trial.

4

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.

Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim YM, Guerra EM, Sanli UA, McCormack MM, Smith AD, Keefe S, Bird S, Dutta L, Orlowski RJ, Lorusso D; Study 309–KEYNOTE-775 Investigators. Makker V, et al. N Engl J Med. 2022 Feb 3;386(5):437-448. doi: 10.1056/NEJMoa2108330. Epub 2022 Jan 19. N Engl J Med. 2022. PMID: 35045221 Clinical Trial.

5

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.

Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators. Tsuboi M, et al. N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272535 Clinical Trial.

6

VAV1-overexpressing YT cells display improved cytotoxicity against malignant cells.

Smagina AS, Kulemzin SV, Yusubalieva GM, Kedrova AG, Sanzharov AE, Ivanov YV, Matvienko DA, Kalsin VA, Gorchakov AA, Baklaushev VP, Taranin AV. Smagina AS, et al. Among authors: kedrova ag. Biotechnol Appl Biochem. 2021 Aug;68(4):849-855. doi: 10.1002/bab.2001. Epub 2020 Aug 21. Biotechnol Appl Biochem. 2021. PMID: 32767384

7

Sensitivity of human lymphocytes to genotoxic effect of n-methyl-n-nitrosourea: possible relation to gynecological cancers.

Tronov VA, Kramarenko II, Kozlova AD, Dederer LJ, Kedrova AG, Gorbacheva LB. Tronov VA, et al. Among authors: kedrova ag. Exp Oncol. 2006 Dec;28(4):314-8. Exp Oncol. 2006. PMID: 17285117

8

[Treatment of chronic cardiac insufficiency by combined use of adrenergic beta receptor blockaders and cardiac glycosides].

Kedrov AA, Kedrova AN, Somova LV. Kedrov AA, et al. Among authors: kedrova an. Klin Med (Mosk). 1978 Jan;56(1):33-7. Klin Med (Mosk). 1978. PMID: 633796 Russian. No abstract available.

9

[Secondary displacement in conservative treatment of ankle fractures].

Kedrova AN. Kedrova AN. Ortop Travmatol Protez. 1977 Jan;(1):30-3. Ortop Travmatol Protez. 1977. PMID: 854285 Russian. No abstract available.

10

[Results of surgical treatment of Dupuytren's contracture].

Kedrova AN, Luchko GD, Lur'e NG. Kedrova AN, et al. Ortop Travmatol Protez. 1974 Apr;35(4):30-4. Ortop Travmatol Protez. 1974. PMID: 4602704 Russian. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

15 results

Search Page